Life Sciences Financial Statements: What Investors Expect (and What CPAs Fix)

Financial reporting is an essential accounting practice for all businesses. Factual financial reports inform planning and critical business decisions and are required for stakeholder edification, especially in life sciences, which relies heavily on funding from investors and grant organizations.

Though every business does it, financial reporting in life sciences looks a bit different. The capital-intensive, milestone-driven aspect of this industry is unique. Long pre-revenue timelines must be justified with progress, and financial statements can validate the story.

Ultimately, investors are buying into future potential. Financial reports can directly affect valuation and fundraising, so quality, accuracy, and transparency are must-haves.

Today’s article will drill down on what investors want to see and what a qualified CPA can help you fix.

What Investors Focus on in Financial Statements

As noted above, investors in the life sciences sector are concerned with factors beyond profitability. Since most startups in this space are pre-revenue, long-term potential must be assessed, with the balance sheet providing a gauge of the company’s long-range prospects.

With that in mind, the most critical aspects of life sciences financial statements must include the following:

Cash Runway and Burn Rate

Without capital, nothing moves forward. Financial reports should address the monthly burn in simple terms and how many months of runway are reasonably expected.

The statements should demonstrate alignment beyond the math itself: will your plan carry the company through regulatory milestones, or will another raise be needed? Timing is everything and matters almost as much as the science.

If runway appears to fall short, it signals risk. Your statements need to show that you are not just forging ahead unquestioningly, but are taking every opportunity to manage capital strategically.

Aligning R&D Spending 

Costs should be itemized and clearly distinguished between research-related vs. commercially-related costs.

Spending should align with pipeline claims to demonstrate alignment and support transparency.

Revenue Quality (Commercial Stage)

Revenue quality becomes primary at the commercial stage. Statements should clearly distinguish between recurring product revenue vs. milestone revenue, the latter of which is often a one-time thing. The point here is that sustainable revenue has more weight than periodic spikes.

Proper application of ASC 606 is critical, especially regarding performance milestones and the timing of revenue recognition.

Gross-to-net accuracy must also be prioritized, taking into account chargebacks, discounts, rebates, and returns. The more transparent the revenue report is, the more confident investors will be that your growth is sustainable.

IP and Intangible Assets

IP is, inarguably, one of the most important aspects of a company’s value and the balance sheet. Valuations must be grounded in reality rather than optimistic assumptions.

Setbacks and delays are possible and must be factored in. Examples of things that could affect cash flow projections include clinical issues, regulatory delays, and market changes.

Be up front about valuation methods and impairment testing to help investors understand the risks. Demonstrating that you understand them, too, shows maturity and helps to build confidence.

Dilution and Capital Structure

Keep in mind that today’s financing decisions will have a direct impact on tomorrow’s ownership. Convertible debt, warrants, and stock-based compensation can affect future equity, so statements should not just show what’s outstanding, but also what can be converted or vested based on various scenarios.

Disclosing share issuance plans, terms, and triggers helps to illuminate risks and mitigate issues in future funding rounds.

What Can CPAs Fix?

CPAs are strategic partners for life sciences companies, as they understand what matters most and can help cut through the financial noise. Life sciences CPAs are also specialists in sector-specific regulations and can set up financials to ensure they meet GAAP standards.

Here are a few errors CPAs can fix.

Accurate Revenue Recognition

Improper milestone recognition is one of the most common errors we see. For example, there is a difference between whether the milestone is probable or if money was actually received.

Misapplied performance obligations and gross-to-net adjustments are other areas of concern. Revenue must be recognized separately based on what it is for, i.e., development funding, upfront fees, etc., or in the case of gross-to-net, fixing errors in returns or chargebacks that misrepresent revenue.

Proper R&D and Cost Classification

Incorrect capitalization vs. immediate expensing, and misclassified expenses must be corrected to align with associated costs and grant funding.

Stock Compensation and 409A Gaps

Inaccurate fair value calculations are frequently associated with outdated or incorrect 409A valuations. If left unchecked, this can cause issues during an audit or due diligence. Valuations must be defensible and should be supported by realistic assumptions. Missing or incomplete disclosures tend to amplify the situation and may erode investor confidence.

Lease Accounting (ASC 842) 

Unrecorded or misclassified lab/equipment leases can be a problem if they are inaccurately recorded on the balance sheet. A CPA can help to identify and correct these mistakes before they become a tax burden.

Weak Internal Controls and Closing Process

Poor documentation, inaccurate accruals, and a lack of audit readiness can quickly become problematic. Best practices should be implemented to avoid the risk of fraud. Tactics include segregation of duties, standardized processes and documentation, IT controls, asset and inventory management policies, and frameworks for identifying revenue recognition risks, among other measures.

The Bottom Line: Clean Financial Statements Accelerate Growth

Investors expect credibility, consistency, and transparency. CPAs deliver deep regulatory knowledge, can implement strong controls, and deliver clarity and understanding that protects the company from risk at every stage of growth.

Early-stage companies need a clean cap table that shows all equity ownership, clearly defines the runway, and aligns with GAAP standards.

Clinical-stage companies precisely track trial expense accruals to ensure expenses match the financial statements, and track milestones to connect revenue, expenses, and cash payments to the proper source.

Commercial-stage companies require revenue accuracy, inventory controls, and gross-to-net controls that comply with applicable standards, such as ASC 606.

To ensure success, Pre-IPO or M&A transactions require audit readiness, and financial statements must demonstrate the quality of earnings and SEC compliance.

Bottom line? Life sciences financial statements are complex. An experienced CPA can help you navigate the landscape, identify risk, and set you up for success.

Book a call with a Growise expert today, and let’s talk about your company’s future.